Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Diagnosis and Treatment Rate among Patients with MPS
4.1.1.2. Rising Novel Product Approvals
4.1.2. Restraints
4.1.2.1. Limited availability of approved drugs
4.1.2.2. Patient compliance issues
4.1.2.3. XX
4.1.3. Opportunities
4.1.3.1. Rising Access in Emerging Countries
4.1.3.2. XX
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. MPS I (Hurler Syndrome)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. MPS II (Hunter Syndrome)
6.4. MPS IV (Morquio Syndrome)
6.5. MPS VI (Maroteaux-Lamy Syndrome)
6.6. MPS VII (Sly Syndrome)
6.7. Others
7. By Drug
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
7.1.2. Market Attractiveness Index, By Drug
7.2. Laronidase*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Idursulfase
7.4. Pabinafusp Alfa
7.5. Elosulfase Alfa
7.6. Galsulfase
7.7. Vestronidase Alfa-vjbk
7.8. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
Key Market Players
10.1. Sanofi*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Takeda Pharmaceuticals
10.3. GC Biopharma corporate.
10.4. CANbridge Life Sciences Ltd.
10.5. JCR Pharmaceuticals Co., Ltd.
10.6. BioMarin Pharmaceutical Inc.
10.7. Ultragenyx Pharmaceutical Inc.
Emerging Market Players
10.8. Orchard Therapeutics plc
10.9. REGENXBIO Inc.
10.10. NS Pharma, Inc.
10.11. Generium
10.12. ESTEVE
10.13. Inventiva.
10.14. Allievex Corporation
10.15. Paradigm Biopharmaceuticals Ltd.
10.16. Denali Therapeutics
10.17. IMMUSOFT
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us